Evaluation of the outcome of lung nodules missed on $^{18}$F-FDG PET/MRI compared to $^{18}$F-FDG PET/CT in patients with known malignancies

Lino M Sawicki$^1$, Johannes Grueneisen$^2$, Christian Buchbender$^1$, Benedikt M Schaarschmidt$^1$, Benedikt Gomez$^3$, Verena Ruhlmann$^3$, Lale Umutlu$^2$, Gerald Antoch$^1$, Philipp Heusch$^1$

$^1$University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany

$^2$University Duisburg-Essen, Medical Faculty, Department of Diagnostic and Interventional Radiology and Neuroradiology, Essen, Germany

$^3$University Duisburg-Essen, Medical Faculty, Department of Nuclear Medicine, D-45147 Essen, Germany

Corresponding author:

Lino Sawicki

University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, Moorenstrasse 5, D-40225 Dusseldorf, Germany

Tel: +49 (0) 211 - 811 77 54

Telefax: +49 (0) 211 - 8 11 61 45

e-mail: linomorris.sawicki@med.uni-duesseldorf.de
First author:
Lino Sawicki
MD, resident
University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, Moorenstrasse 5, D-40225 Dusseldorf, Germany
Tel: +49 (0) 211 - 811 77 54
Telefax: +49 (0) 211 - 8 11 61 45
e-mail: linomorris.sawicki@med.uni-duesseldorf.de

Word count: 4820

No financial support was provided for this work.

Nothing to disclose.

No conflicts of interest.

Running title: Outcome of lung nodules missed by PET/MR
Abstract

The lower detection rate of $^{18}$F-fluordesoxyglucose positron emission tomography/magnetic resonance imaging ($^{18}$F-FDG PET/MRI) compared to $^{18}$F-FDG PET/computed tomography ($^{18}$F-FDG PET/CT) regarding small lung nodules should be considered in the staging of malignant tumors. The purpose of this study was to evaluate the outcome of these small lung nodules missed by $^{18}$F-FDG PET/MRI.

Material and Methods: Fifty-one oncologic patients (mean age: 56.6±14.0 years; 29 female, 22 male; tumor stages: I (n=7), II (n=7), III (n=9), IV (n = 28)) who underwent $^{18}$F-FDG PET/CT and subsequent $^{18}$F-FDG PET/MRI on the same day were retrospectively enrolled. Images were analyzed by two readers in random order and separate sessions with a minimum of four weeks apart. A maximum of ten lung nodules was identified for each patient on baseline imaging. Presence, size and presence of focal tracer uptake was noted for each lung nodule detected on $^{18}$F-FDG PET/CT and $^{18}$F-FDG PET/MRI using a postcontrast T1-weighted (T1w) 3 dimensional (3D) gradient echo (GRE) volume-interpolated breathhold-examination (VIBE) sequence with fat suppression (fs) as morphological dataset. Follow-up CT or $^{18}$F-FDG PET/CT (mean time-to-follow-up: 11 months, range: 3-35) was used as reference standard to define each missed nodule as benign or malignant based on changes in size and potential new tracer uptake. Nodule-to-nodule comparison between baseline and follow-up was performed using descriptive statistics.

Results: Out of 134 lung nodules found on $^{18}$F-FDG PET/CT, $^{18}$F-FDG PET/MRI detected 92 nodules. Accordingly, 42 lung nodules (average size: 3.9±1.3 mm; range: 2–7 mm) were missed by $^{18}$F-FDG PET/MRI. None of the missed lung nodules presented with focal tracer
uptake on baseline imaging or follow-up $^{18}$F-FDG PET/CT. Thirty-three out of 42 missed lung nodules (78.6 %) in 26 patients were rated benign, whereas 9 nodules (21.4 %) in four patients were rated malignant. As a result, one patient required upstaging from tumor stage I to IV.

**Conclusion:** Although the majority of small lung nodules missed on $^{18}$F-FDG PET/MRI was found to be benign there was a relevant number of undetected metastases. However, in patients with advanced tumor stages the clinical impact remains controversial as upstaging is usually more relevant in lower stages.

**Key words:** lung, nodules, MRI, PET/MRI, PET/CT
Introduction

Metastatic spread to the lungs commonly implies a higher tumor stage in patients suffering from malignant diseases often requiring a change of therapy regimens and ultimately decreasing chances of survival (1). Hence, early detection of potential pulmonary metastases is essential. Due to a higher accuracy in tumor, nodal and distant metastasis (TNM) staging than either positron emission tomography (PET) or computed tomography (CT) alone (2), integrated $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) PET/CT has been implemented in the staging routine of a growing number of tumor entities and is regarded as the standard of reference by many authors (3-5). Magnetic resonance imaging (MRI) on the other hand, offers superior sensitivity compared to CT concerning infiltration of the primary tumor into adjacent organs and detection of metastasis to parenchymatous organs like the liver, the brain or the kidneys (6-8). In addition, MRI provides valuable functional information from quantitative and multi-parametric imaging (9). With the introduction of fully integrated PET/MRI systems, PET and MRI can be used synergistically in a single modality taking advantage of an exact correlation between FDG-avid lesions and the anatomic details obtained by MR images (10-12). Yet, regarding lung imaging, even when using high spatial resolution T1-weighted (T1w) 3 dimensional (3D) gradient echo (GRE) sequences (e.g. volume-interpolated breathhold-examination (VIBE)) recommended for the identification of small pulmonary nodules (13-15), PET/MRI seems to be outmatched by PET/CT (16). Underlying reasons are found in PET/MRI’s lower sensitivity regarding $^{18}$F-FDG-negative lesions (17, 18) owing to a low proton density in aerated lungs, fast decay of signal caused by susceptibility artifacts at air-tissue boundaries, and motion artifacts caused by breathing and cardiac pulsation. Bearing in mind the increasing utilization of whole-body PET/MRI, its lower detection rate of small lung nodules potentially representing metastases should be considered in the staging of malignant
tumors. Hence, the purpose of this study was to evaluate the outcome of small lung nodules detected on \(^{18}\)F-FDG PET/CT but missed by \(^{18}\)F-FDG PET/MRI in terms of their presumed dignity.

**Materials and Methods**

**Patients and inclusion criteria**

Patients with a known malignancy (TABLE 1) who underwent \(^{18}\)F-FDG PET/MRI including a postcontrast, fat suppressed (fs) T1w VIBE sequence of the thorax following clinically indicated \(^{18}\)F-FDG PET/CT for tumor staging on the same day were retrospectively enrolled in this study. A follow-up CT or \(^{18}\)F-FDG PET/CT not less than three months after the initial examination had to be available for outcome evaluation. According to these criteria, a total of 51 patients (mean age: 56.6 ± 14.0 years; 29 female, 22 male) between May 2012 and December 2014 were eligible for retrospective analysis. The study cohort comprised patients with tumor stages I (n = 7), II (n = 7), III (n = 9), and IV (n = 28). Eight out of 51 patients were suffering from a recurrent malignancy. The study was approved by the local ethics committee and all subjects signed an informed consent form.

**PET/CT Imaging**

Patients underwent whole-body (i.e. head to upper thighs) \(^{18}\)F-FDG PET/CT on a Biograph mCT or Biograph Duo (Siemens AG, Healthcare Sector, Erlangen, Germany) 61 ± 8 minutes after intravenous injection of a mean activity of 260 ± 60 MBq \(^{18}\)F-FDG, depending on their body weights. At injection time, blood glucose levels needed to be below 150 mg/dl. Twenty-three patients were examined in low-dose CT technique. In 28 patients full-dose CT scans were performed. Full-dose CT scans were conducted after intravenous injection of a contrast
agent (Imeron 300, Bracco Imaging Deutschland GmbH, Konstanz, Germany). In all full-dose PET/CT scans an additionally acquired, dedicated lung scan applying a sharp b 70 or b 90 kernel in deep inspiration was used for the detection of lung nodules. CT images were displayed on lung window setting and using a slice thickness of 2 mm. For dose reduction purposes, the manufacturer-supplied solutions CareKV and CareDose 4D were used for both full- and low-dose PET/CT scans (presets: 120kV; 210mAs and 120kV; 40 mAs, respectively). PET-acquisition time using static frames varied from 2 – 3.5 minutes per bed position. Iterative reconstruction (3 iterations, 21 subsets) with a Gaussian filter of 4.0 mm was applied. In general, the slice thickness of reconstructed PET images was 3 mm. For attenuation correction of the PET dataset, the portal venous phase of full-dose CT scans and low-dose CT data in low-dose scans were used.

**PET/MR Imaging**

Whole-body (i.e. head to upper thighs) $^{18}$F-FDG PET/MRI using Flex coils (Siemens Healthcare AG, Erlangen, Germany) was performed on a 3 Tesla Biograph mMR (Siemens Healthcare AG, Erlangen, Germany). The average delay after intravenous tracer injection was 117 ± 29 minutes. For morphologic assessment of the lungs, a transverse T1w fs VIBE sequence (TR 4.08 ms, TE 1.51 ms, slice thickness 3.5 mm, FOV 400 x 300 mm, matrix size 512 x 307.2 mm, voxel size: 1.3 x 0.8 x 3.5 mm) after contrast administration (Dotarem, Guerbet GmbH, Sulzbach, Germany) was acquired. Attenuation correction was based on a coronal 3D-Dixon-VIBE sequence (TR 3.6 ms, TE1 1.23 ms, TE2 2.46 ms, slice thickness 3.12 mm, FOV 500 x 328 mm, matrix size 192 x 121 mm, voxel size: 4.1 x 2.6 x 3.1 mm). In general, PET acquisition time was 3 minutes per bed position. PET images were acquired in list mode and reconstructed using iterative algorithm ordered-subsets expectation
maximization, 3 iterations and 21 subsets. A Gaussian filter of 4.0 mm was applied. In general, the slice thickness of reconstructed PET images was 3 mm.

Follow-up imaging
Chest CT (n = 32) and whole-body $^{18}$F-FDG PET/CT (n = 19) scans were considered appropriate for follow-up imaging and categorization of dignity of the missed lung nodules. Follow-up CT examinations - if available - were conducted on one of the following CT scanners: Definition AS+, Definition Flash, Definition Force (Siemens Healthcare, Erlangen, Germany). Follow-up $^{18}$F-FDG PET/CT examinations were carried out on the aforementioned Biograph mCT or Biograph Duo (Siemens Healthcare AG, Erlangen, Germany). Baseline and follow-up examinations had to be a minimum of 3 months apart. For follow-up imaging the most recent CT or $^{18}$F-FDG PET/CT was selected. The average follow-up interval imaging was 11 ± 8 months (range: 3-35 months). TABLE 2 gives an overview of patient numbers and tumor types in different follow-up intervals.

Image analysis
Images were evaluated on a dedicated OsiriX Workstation (Pixmeo SARL, Bernex, Switzerland). Baseline $^{18}$F-FDG PET/CT and $^{18}$F-FDG PET/MRI datasets as well as follow-up CT or $^{18}$F-FDG PET/CT scans were analyzed by two independent radiologists with three and five years of experience in hybrid imaging. Readers were aware of patients’ diagnosis. Any discrepancies between the two readers were resolved in a subsequent consensus reading. PET images were reviewed with and without attenuation correction of the PET data to prevent false-positive findings caused by attenuation-correction artifacts. Baseline $^{18}$F-FDG PET/CT and $^{18}$F-FDG PET/MRI were assessed in random order and in separate sessions with a
minimum of four weeks apart to avoid recognition bias. Morphologic T1w fs VIBE and CT images as well as PET from PET/CT and PET from PET/MRI were analyzed separately and as fused datasets. Presence, size (i.e. longitudinal axis diameter on transverse images) on the CT component of $^{18}$F-FDG PET/CT and presence of focal tracer uptake above surrounding background was noted for each lung nodule detected on $^{18}$F-FDG PET/CT and on $^{18}$F-FDG PET/MRI. Initially, a maximum of ten lung nodules was identified for each patient on baseline imaging, beginning with the right upper lobe proceeding to the left lower lobe. Each lung nodule found on $^{18}$F-FDG PET/CT but not detected on $^{18}$F-FDG PET/MRI was rated a missed nodule. In a separate session, the size of each missed lung nodule was reassessed on follow-up CT or $^{18}$F-FDG PET/CT, respectively. In cases, in which a PET/CT was available for follow-up, missed nodules were also analyzed in regard of a potential new $^{18}$F-FDG uptake.

**Standard of reference**

Since histopathological correlation could not be obtained for any of the missed lung nodules, the standard of reference to determine the outcome of a missed lung nodule was based on a) change in nodule size between baseline and follow-up imaging (Chest CT or $^{18}$F-FDG PET/CT) and b) presence of new $^{18}$F-FDG avidity of a lung nodule on follow-up PET/CT. Potential systemic therapy was addressed as follows: Nodules presenting smaller on follow-up were rated malignant if the patient underwent systemic cancer therapy during the time of follow-up (i.e. therapy effect) or rated benign provided no cancer therapy had been administered. Nodules presenting constant in size were rated benign, regardless of whether the patient received cancer therapy or not. This procedure for nodules constant in size was decided on to avoid overestimation of the number of metastases while acknowledging that the
overall number of metastases may have been underestimated by this approach. Nodules with an increased size on follow-up or a new $^{18}$F-FDG avidity on follow-up PET/CT were rated malignant (FIGURE 1).

**Statistics**

IBM SPSS Statistics 22 (IBM, Armonk, NY, USA) was used for statistical analysis. All data are given in mean ± standard deviation. Descriptive analysis was used for the calculation of the patients’ characteristics and for follow-up nodule-to-nodule comparison. Similar to previous reports (19) reliability between readers was performed in a descriptive way.

**Results**

There was 97 % agreement between both readers on all lung nodules detected by $^{18}$F-FDG PET/CT and $^{18}$F-FDG PET/MRI with only 3% needing a consensus reading, in which agreement was found in all cases. In 51 patients a total of 134 lung nodules were found on $^{18}$F-FDG PET/CT (mean size: 12.9 mm ± 15.7 mm; range: 2 mm - 98 mm; 0 - 10 lung nodules per patient). $^{18}$F-FDG PET/MRI detected 92 of these lung nodules signifying a detection rate of 68.7 %. $^{18}$F-FDG PET/MRI and $^{18}$F-FDG PET/CT detected concordant numbers of lung nodules in 21 patients, nine of which did not exhibit any lung nodules. In the other 30 patients, 42 lung nodules were missed on $^{18}$F-FDG PET/MRI but detected on $^{18}$F-FDG PET/CT (FIGURE 2). The percentage of missed nodules with respect to the total number of lung nodules was 31.3 %. The mean size of the missed nodules was 3.9 mm ± 1.3 mm, range: 2 – 7 mm (FIGURE 3). On average, 0.8 pulmonary nodules per patient were missed on $^{18}$F-FDG PET/MRI compared to $^{18}$F-FDG PET/CT. None of the missed lung nodules presented with
focal $^{18}$F-FDG-uptake above the surrounding background on baseline attenuation-corrected or non-attenuation-corrected PET images. Nodule-to-nodule follow-up assessment revealed that 71.4 % (30/42) of missed lung nodules remained constant in size, 26.2 % (11/42) of missed lung nodules decreased in size or completely resolved, and 2.4 % (1/42) of lung nodules increased in size on follow-up CT or $^{18}$F-FDG PET/CT compared to baseline imaging. None of the missed lung nodules demonstrated a new tracer uptake on follow-up $^{18}$F-FDG PET/CT. 70 % (21/30) of the patients with missed lung nodules received systemic or local cancer therapy in the interval of baseline PET/MRI or PET/CT and follow-up CT or $^{18}$F-FDG PET/CT, whereas 30 % (9/30) of the patients were not subjected to cancer therapy. According to the reference standard, 78.6 % (33/42) of the missed pulmonary nodules in 26 out of 30 (86.7 %) patients were rated benign, whereas 21.4 % (9/42) of the missed pulmonary nodules in four out of 30 (13.3 %) patients were rated malignant (FIGURES 4, 5). Due to the occurrence of a new metastatic spread to the right lung upstaging from tumor stage I to IV was required in one of the four patients. This patient was initially diagnosed with a T1 N0 M0 non-small cell lung cancer in the contralateral lung. As a consequence, the contralateral lung metastasis demanded restaging to M1a (20). As distant metastases had already been diagnosed in the other three patients, no adjustment of TNM staging was necessary in these cases.

**Discussion**

The intention of this study was to evaluate the outcome of small lung nodules detected on $^{18}$F-FDG PET/CT, which were not identifiable on $^{18}$F-FDG PET/MRI in oncologic patients. According to the reference standard, the majority (78.6 %) of these missed lung nodules was rated as benign but there was a small but relevant number (21.4 %) of undetected lung nodules that were suspicious of metastases.
The detection of small lung nodules is a key clinical demand in cancer staging as potential metastatic spread can have far-reaching effects on therapy and patient survival (1, 13, 20). Today, whole-body $^{18}$F-FDG PET/CT is widely available and used not only to identify lung nodules but also to discriminate malignant from benign pulmonary masses enabling a comprehensive tumor staging in a one-stop shop examination (21-23). On the other hand, the latest transition from a mere research modality into clinical practice raised issues regarding the eligibility of $^{18}$F-FDG PET/MRI to detect small pulmonary nodules compared to CT or PET/CT as the modality of choice for lung imaging.

None of the missed lung nodules, including those that were suspicious of metastasis, presented with a focal tracer uptake on the PET component of $^{18}$F-FDG PET/CT or $^{18}$F-FDG PET/MRI. However, given the fact that 21.4 % of non-FDG-avid nodules were likely malignant, our results indicate that PET-negativity is not suitable to rule out malignancy in small lung lesions. Studies by Yilmaz et al., Farid et al., and Khalaf et al. demonstrating a high prevalence of PET-negativity in malignant nodules < 1 cm have corroborated these results (24-26). False negative findings might have been attributed to breathing motion, low metabolic activity (27), small nodule size, and the limited spatial resolution of PET leading to a substantial underestimation of the true activity within the lesion (8). Moreover, differences between $^{18}$F-FDG PET/MRI and $^{18}$F-FDG PET/CT regarding PET reconstruction parameters as for instance slice thickness can influence nodule detectability of the PET component. With a slice thickness of around 3 mm for PET from $^{18}$F-FDG PET/MRI and from $^{18}$F-FDG PET/CT both PET components could be considered equally prone to partial volume effects in our study. However, considering that a relevant proportion of nodules were ≤ 3 mm in size partial volume effects might have been a relevant factor.
From the variety of clinically used MR sequences of the thorax, T1w 3D GRE sequences like VIBE offer the highest detection rates of small pulmonary nodules and thus served as the only morphologic dataset in this study (13-15, 28-30). Performed in a comparatively short imaging time (approximately 20 sec), they allow for an acquisition during breath-hold with accurate fusion of simultaneously acquired PET signals (31). Further advantages encompass high spatial resolution offering high quality depiction of lung anatomy and a lower rate of artifacts compared to 2D GRE sequences (32). However, comparative studies examining the sensitivity of MRI and CT for lung nodules < 1 cm found that MRI still lags behind CT with detection rates ranging between 80 % and 90 %, (14, 17, 30, 33). Signal loss because of cardiac pulsation and respiration, susceptibility artifacts arising from multiple air-tissue interfaces, and low proton density in aerated lungs are known drawbacks hampering the identification of small pulmonary nodules (34). With a detection rate of approximately 70 % for lung nodules < 0.7 cm, our results seem to support these prior investigations.

Among four patients with suspected lung metastases that were missed by 18F-FDG PET/MRI two patients each were suffering from lung and breast cancer; two entities renowned for a high potential of developing lung metastases and thus further substantiating the suspicion of malignancy (35, 36). However, as in three out of the four patients distant metastases had already been diagnosed a missed metastatic spread to the lungs should not be expected to have high therapeutic significance. A clinically relevant upstaging from tumor stage I to IV was required in only one of the patients. For all other patients with lung nodules missed by 18F-FDG PET/MRI no adjustment of TNM staging was required. Given that the majority of missed lung nodules proved benign and upstaging seems to be necessary only in exceptional cases, thus, from a clinical standpoint our results may generally endorse the utilization of whole-body 18F-FDG PET/MRI in oncologic patients. Nevertheless, this is partly due to study-specific
patient characteristics, which mainly included patients with very advanced tumor stages. The evaluation of consequences on treatment decisions and prognosis might be addressed in future projects.

This study has some limitations. One limitation was the small and heterogeneous patient cohort comprising different tumor entities with a varying degree of metastatic potential and FDG-avidity. The use of two different PET/CT protocols (one with additional low-dose CT of the chest in maximal inspiration, one without) may have led to underestimation of the overall number of pulmonary nodules on the reference standard. Adding a low-dose CT in maximal inspiration should be a prerequisite when designing a follow-up study addressing a potential effect of missed pulmonary metastases on patient management. Also, the slice thickness of the CT component of baseline $^{18}$F-FDG PET/CT was 2 mm, whereas the slice thickness of T1w fs VIBE of $^{18}$F-FDG PET/MRI was 3.5 mm. Bearing in mind that missed lung nodules measured around 4 mm the larger slice thickness of T1w fs VIBE might have contributed to the inferior detection rate of $^{18}$F-FDG PET/MRI. However, T1w VIBE images of the chest are not yet feasible with a lower slice thickness than 3.5 mm. It could be assumed that the MRI component might have performed better using a lower slice thickness. However, technical requirements are yet to be introduced into clinical routine. It also has to be considered that a minor part of lung nodules presenting smaller in patients undergoing cancer therapy might still have been of infectious origin. In this case the number of missed metastases may have been overestimated. Furthermore, some of the nodules that remained constant in size on follow-up might have represent metastases with partial response to systemic or local cancer therapy. Although the mean follow-up interval was eleven months many patients had follow-up intervals of less than six months. In slowly growing lesions one might argue that it was difficult to exclude false negative readings. Lacking a histopathological reference standard these
limitations have to be kept in mind when interpreting the results of this study.

**Conclusion**

Due to its lower sensitivity in detecting PET-negative lung nodules, whole-body $^{18}$F-FDG PET/MRI using a T1w VIBE sequence misses a relevant proportion of small lung nodules in oncologic patients. Although the majority of missed lung nodules proved to be benign there is a considerable number of metastases among those missed nodules. However, in patients with very advanced tumor stages the clinical impact remains controversial as potential upstaging is usually more relevant in lower tumor stages.

**Disclosure**

No financial support was provided for this work. There were no conflicts of interest.

**Acknowledgements**

None.
References


FIGURE 1. Flowchart to determine the outcome of lung nodules missed by $^{18}$F-FDG PET/MRI.
FIGURE 2. Images of a 50-year-old female patient suffering from breast cancer. Five mm lung nodule located in the right upper lobe (arrows in A and C) identified on the CT images (A) of $^{18}$F-FDG PET/CT (E) but not recognizable on T1w fs VIBE images (D) of $^{18}$F-FDG PET/MRI (F). There was no corresponding FDG-uptake on PET from PET/CT (B) and on PET from PET/MRI (E).
FIGURE 3. Sizes of 42 missed lung nodules measured on $^{18}$F-FDG PET/CT. Average size of the nodules was 3.9 mm (broken line). Minimum and maximum sizes were 2 and 7 mm, respectively.
FIGURE 4. 47-year-old female patient suffering from breast cancer. Five mm lung nodule located in the right lower lobe (arrows in A and C) identified on the CT component (A) of ¹⁸F-FDG PET/CT images (C) but not detectable on T1w fs VIBE images (D) of ¹⁸F-FDG PET/MRI. No focal FDG-uptake was seen on PET from PET/CT (B) and PET from PET/MRI (E). After chemotherapy, 3 months follow-up CT revealed complete disappearance of the nodule (F). Note the focal FDG-uptake attributable to a left hilar lymph node metastasis (B, C, E).
FIGURE 5. Development of nodule size comparing baseline and follow-up images (A).

Outcome of lung nodules according to the standard of reference (B).
Tables

**TABLE 1.** Tumor entities within the study cohort sorted by frequency.

<table>
<thead>
<tr>
<th>Tumor</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer</td>
<td>12</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>8</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>7</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>5</td>
</tr>
<tr>
<td>Gastrointestinal cancer</td>
<td>3</td>
</tr>
<tr>
<td>Malignant melanoma</td>
<td>3</td>
</tr>
<tr>
<td>Malignant mesothelioma</td>
<td>3</td>
</tr>
<tr>
<td>Other (&lt; 3 cases/entity)</td>
<td>10</td>
</tr>
</tbody>
</table>
TABLE 2. Tumor entities in three different follow-up intervals sorted by frequency.

<table>
<thead>
<tr>
<th>3 – 6 months (n)</th>
<th>6 – 12 months (n)</th>
<th>&gt; 12 months (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer (10)</td>
<td>Ovarian cancer (4)</td>
<td>Colorectal cancer (2)</td>
</tr>
<tr>
<td>Breast cancer (5)</td>
<td>Breast cancer (3)</td>
<td>Ovarian cancer (2)</td>
</tr>
<tr>
<td>Lymphoma (3)</td>
<td>Lung cancer (2)</td>
<td>Malignant melanoma (2)</td>
</tr>
<tr>
<td>Sarcoma (2)</td>
<td>Lymphoma (2)</td>
<td>Uterine cancer (1)</td>
</tr>
<tr>
<td>Mesothelioma (2)</td>
<td>Mesothelioma (1)</td>
<td>Head and neck cancer (1)</td>
</tr>
<tr>
<td>Ovarian cancer (1)</td>
<td>Sarcoma (1)</td>
<td></td>
</tr>
<tr>
<td>Uterine cancer (1)</td>
<td>Thyroid cancer (1)</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer (1)</td>
<td>Cervical cancer (1)</td>
<td></td>
</tr>
<tr>
<td>Cholangiocellular cancer (1)</td>
<td>Malignant melanoma (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uterine cancer (1)</td>
<td></td>
</tr>
<tr>
<td><strong>Total = 26</strong></td>
<td><strong>Total n = 17</strong></td>
<td><strong>Total n = 8</strong></td>
</tr>
</tbody>
</table>
Evaluation of the outcome of lung nodules missed on $^{18}$F-FDG PET/MRI compared to $^{18}$F-FDG PET/CT in patients with known malignancies

Lino Morris Sawicki, Johannes Grueneisen, Christian Buchbender, Benedikt Michael Schaarschmidt, Benedikt Gomez, Verena Ruhlmann, Lale Umutlu, Gerald Antoch and Philipp Heusch

*J Nucl Med.*
Published online: October 29, 2015.
Doi: 10.2967/jnumed.115.162966

This article and updated information are available at:
http://jnm.snmjournals.org/content/early/2015/10/28/jnumed.115.162966

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

*JNM* ahead of print articles have been peer reviewed and accepted for publication in *JNM*. They have not been copyedited, nor do they appear in a print or online issue of the journal. Once the accepted manuscripts appear in the *JNM* ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.

*The Journal of Nuclear Medicine* is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2015 SNMMI; all rights reserved.